A61K 31/5375
1,4-oxazines
Official title: 1,4-Oxazines, e.g. morpholine
A61K31/5375 (1,4-oxazines) appears on 8,310 US grants and 15,247 published applications in this corpus.
Search patents in A61K- Granted patents
- 8,310
- Published applications
- 15,247
- Assignees
- 3,957
- Inventors
- 29,159
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 7 | 0 |
| 1996 | 18 | 0 |
| 1997 | 39 | 0 |
| 1998 | 39 | 0 |
| 1999 | 43 | 0 |
| 2000 | 63 | 0 |
| 2001 | 71 | 31 |
| 2002 | 81 | 120 |
| 2003 | 78 | 203 |
| 2004 | 74 | 194 |
| 2005 | 54 | 199 |
| 2006 | 84 | 241 |
| 2007 | 75 | 243 |
| 2008 | 90 | 217 |
| 2009 | 103 | 288 |
| 2010 | 107 | 357 |
| 2011 | 144 | 397 |
| 2012 | 233 | 417 |
| 2013 | 356 | 711 |
| 2014 | 467 | 933 |
| 2015 | 597 | 1014 |
| 2016 | 667 | 995 |
| 2017 | 762 | 969 |
| 2018 | 640 | 833 |
| 2019 | 628 | 796 |
| 2020 | 527 | 797 |
| 2021 | 469 | 821 |
| 2022 | 399 | 750 |
| 2023 | 329 | 791 |
| 2024 | 380 | 975 |
| 2025 | 398 | 1080 |
| 2026 | 282 | 875 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- CDK inhibitors6 Oct 2026US 12,751,951 B2Genentech, Inc.
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Small molecule inhibitors of viral replication6 Oct 2026US 12,751,963 B2The Trustees of Princeton University
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Drug-containing particle8 Oct 2026US 2026/0306409 A1Towa Pharmaceutical Co., Ltd.
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Pim1 inhibitor for treating myeloproliferative neoplasms8 Oct 2026US 2026/0306490 A1Sumitomo Pharma America, Inc.
- Use of reboxetine to treat narcolepsy8 Oct 2026US 2026/0306501 A1Axsome Therapeutics, Inc.
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators251US 7,247,625 B2Wyeth · 2007
- Treatment of female sexual dysfunction239US 5,877,216 AVivus, Inc. · 1999